Modified Oligonucleotide Modulation of Kallikrein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate kallikrein mRNA and protein expression, particularly in treating hereditary angioedema (HAE), a condition characterized by excessive bradykinin production due to C1-INH deficiency, leading to recurrent episodes of swelling and potential life-threatening laryngeal edema.
Innovation Solution
A modified oligonucleotide, comprising 12 to 30 linked nucleosides that are at least 90% complementary to the KLKB1 nucleic acid, is administered to reduce kallikrein mRNA and protein levels, thereby inhibiting the kallikrein pathway and mitigating inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modified oligonucleotide is administered to reduce kallikrein expression, then inflammatory conditions are treated, but current methods fail to effectively modulate kallikrein mRNA and protein expression
Solution Approach 1:
The patent modifies oligonucleotide parameters including length (12-30 nucleosides), composition (90%+ complementarity to KLKB1), and chemical structure to optimize kallikrein expression modulation. These parameter changes enable effective reduction of kallikrein mRNA and protein levels, resolving the inadequacy of current methods
Solution Approach 2:
The invention uses modified oligonucleotides that are complementary copies of the KLKB1 mRNA sequence. These oligonucleotide copies bind to the target mRNA to inhibit translation and reduce protein expression, providing an effective mechanism that current methods lack
2Object-affected harmful factors
If kallikrein pathway is inhibited to treat HAE, then bradykinin production is reduced, but recurrent episodes of swelling and laryngeal edema persist with current treatments
Solution Approach 1:
The modified oligonucleotide is administered prophylactically to inhibit kallikrein expression before HAE episodes occur. This preliminary action reduces kallikrein mRNA and protein levels in advance, preventing excessive bradykinin production and recurrent swelling episodes, including life-threatening laryngeal edema
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces kallikrein levels in a time- or dose-dependent manner, providing prophylactic, therapeutic, and ameliorative benefits for inflammatory conditions, including HAE, by decreasing vascular permeability and inflammation.
Implementation Method 1
the modified oligonucleotide is at least 90% complementary to a KLKB 1 nucleic acid
Data Source
Figure 1
Figure 2
AI summary
Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.